Trypanosoma cruzi: analysis of two different strains after piplartine treatment

The hemoflagellate protozoan, Trypanosoma cruzi, mainly transmitted by triatomine insects through blood transfusion or from mother-to-child, causes Chagas’ disease. This is a serious parasitic disease that occurs in Latin America, with considerable social and economic impact. Nifurtimox and benznida...

Full description

Bibliographic Details
Main Authors: Gabriela Alves Licursi Vieira, Marco Túlio Alves da Silva, Luis Octávio Regasini, Fernando Cotinguiba, Helen Julie Laure, José César Rosa, Maysa Furlan, Regina Maria Barretto Cicarelli
Format: Article
Language:English
Published: Elsevier 2018-05-01
Series:Brazilian Journal of Infectious Diseases
Online Access:http://www.sciencedirect.com/science/article/pii/S1413867017308899
Description
Summary:The hemoflagellate protozoan, Trypanosoma cruzi, mainly transmitted by triatomine insects through blood transfusion or from mother-to-child, causes Chagas’ disease. This is a serious parasitic disease that occurs in Latin America, with considerable social and economic impact. Nifurtimox and benznidazole, drugs indicated for treating infected persons, are effective in the acute phase, but poorly effective during the chronic phase. Therefore, it is extremely urgent to find innovative chemotherapeutic agents and/or effective vaccines. Since piplartine has several biological activities, including trypanocidal activity, the present study aimed to evaluate it on two T. cruzi strains proteome. Considerable changes in the expression of some important enzymes involved in parasite protection against oxidative stress, such as tryparedoxin peroxidase (TXNPx) and methionine sulfoxide reductase (MSR) was observed in both strains. These findings suggest that blocking the expression of the two enzymes could be potential targets for therapeutic studies. Keywords: Trypanosomatids, Proteome, Piplartine, Therapeutic targets
ISSN:1413-8670